Novartis (NVS) announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia previously treated with corticosteroids. Ianalumab plus eltrombopag extended ITP disease control by 45%, based on the primary endpoint of time to treatment failure, which assesses how long patients maintain safe platelet levels during and after the treatment period. The median time to treatment failure for patients receiving ianalumab plus eltrombopag was 2.8 times longer than those on placebo plus eltrombopag. Patients receiving ianalumab plus eltrombopag also achieved a significantly higher rate of sustained platelet count improvement at six months versus placebo plus eltrombopag, meeting the key secondary endpoint. Fatigue improvement, as measured by PROMIS Fatigue, showed a mean reduction of 7.7 points with ianalumab plus eltrombopag versus 3.6 points with placebo plus eltrombopag.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis announces results on breast cancer patients treated with Kisqali
- Novartis upgraded to Overweight from Neutral at JPMorgan
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- FDA shift in drug study requirements sends trial runners lower